Pralsetinib
Brand: Gavreto (global)
Anticancer
RET inhibitor
Pharmacokinetics
| Half-life | 22 hours |
| Tmax | 2 h |
| Protein Binding | 97 % |
| Volume of Distribution | 248 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Take on empty stomach. Avoid strong CYP3A inhibitors/inducers. |
⚠️ Safety & Warnings
Severity: Severe
Adverse Effects:
Interstitial lung disease/pneumonitis, hypertension, hepatotoxicity, neutropenia
Contraindications:
Severe uncontrolled hypertension
Precautions:
CBC & LFT monitoring required; interrupt if suspected ILD/pneumonitis.